ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1524 • ACR Convergence 2021

    COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population

    Suguni Gallappaththy1, Sarah Ifteqar2 and Amr Edrees3, 1University of Missouri Kansas City, Kansas City, KS, 2UMKC, Kansas City, MO, 3UMKC, Overland Park, KS

    Background/Purpose: Patients with autoimmune inflammatory rheumatic disease (AIRD) are at a higher risk for serious infections due to a combination of disease related immune dysfunction…
  • Abstract Number: 1523 • ACR Convergence 2021

    Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution

    Megan Hansen, Danny Zakria and Douglas Johnson, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Since the introduction of the first immune checkpoint inhibitor (ICI) in 2011, they have become widely utilized in the treatment of malignancy. It is…
  • Abstract Number: 1525 • ACR Convergence 2021

    Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial

    Marthe Brun1, Guro Goll1, Kristin Jørgensen2, Joseph Sexton1, Johanna Gehin3, Øystein Sandanger4, Inge Olsen4, Rolf Anton Klaasen4, David Warren4, Cato Mørk5, Tore Kvien1, Jørgen Jahnsen2, Nils Bolstad4, Espen Haavardsholm1 and Silje Watterdal Syversen1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Akershus University Hospital, Lørenskog, Norway, 3Oslo University Hospital, Lillehammer, Nepal, 4Oslo University Hospital, Oslo, Norway, 5Akershus Dermatology Center, Lørenskog, Norway

    Background/Purpose: Immunogenicity is related to loss of efficacy and safety to TNFα inhibitors and is frequently observed early in the treatment course. The highest rate…
  • Abstract Number: 1522 • ACR Convergence 2021

    Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis

    Anu Desai1, Lakshmi Priya Shadananan1, Adam Croft2, Lalit Pallan1, Neil Steven3 and Benjamin Fisher4, 1University of Birmingham, Birmingham, United Kingdom, 2University of Birmingham, Halesowen, United Kingdom, 3Institute of Immunology and Immunotherapy/University of Birmingham, Birmingham, United Kingdom, 4Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

    Background/Purpose: Immune Check Point Inhibitors (ICIs) are widely used in Oncology and are associated with multiple autoimmune and systemic inflammatory reactions called immune-related adverse events.…
  • Abstract Number: 1529 • ACR Convergence 2021

    Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy

    Huifeng Yun1, Brian LaMoreaux2, Lang Chen3, Stephanie Ledbetter3, Megan Francis-Sedlak2, Kenneth Saag3, Ted Mikuls4 and Jeffrey Curtis5, 1University of Alabama Birmingham, Birmingham, AL, 2Horizon Therapeutics plc, Deerfield, IL, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Nebraska Medical Center, Omaha, NE, 5Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Oral urate-lowering therapy (ULT) is one of the primary treatments for gout. Unfortunately, a proportion of patients with advanced gout are resistant to oral…
  • Abstract Number: 1533 • ACR Convergence 2021

    Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis

    Claudia Marques1, Ana Paula Reis2, Adriana Kakehasi3, Edgard Neto4, Marcelo Medeiros Pinheiro5, Gecilmara Salviato Pileggi6, Gilda Ferreira7, Licia Maria Henrique Mota8, Odirlei Andre Monticielo9, Sandra Lúcia Ribeiro10, Felipe Omura11, Adriana Marinho12, Francinne Ribeiro13, Laurindo Rocha Jr14, Ana Silvia Martins15, Michel Yazbek16, Mariana Souza17, Nathália Sacilotto18, Samuel Shinjo19, Lilian Valadares20, Ana Silva21, Danielle Christine de Brito22, Viviane de Souza23, Carolina Costa24, Samia Studart25, Antônio Ximenes26 and Ricardo Xavier27, 1Hospital das Clnicas - Universidade Federal de Pernambuco - UFPE, Recife, Brazil, 2Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, 3Federal University of Minas Gerais, Belo Horizonte, Brazil, 4UNIFESP, São Paulo, Brazil, 5Universidade Federal de São Paulo, São Paulo, Brazil, 6FACISB, Ribeirao Preto, Brazil, 7Federal University of Minas Gerais, Belo Horizonte, Brazil, 8Universidade de Brasília, Brasilia, Brazil, 9Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 10Universidade Federal do Amazonas, Amazonas, Brazil, 11Clinica Omura, São Paulo, Brazil, 12FUNDHACRE, Rio Branco, Brazil, 13UERJ, Rio de Janeiro, Brazil, 14Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, 15UFU, Uberlandia, MG, Brazil, 16UNICAMP, Campinas, Brazil, 17SCBH, Belo Horizonte, Brazil, 18Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, Brazil, 19Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 20HOSPITAL GETULIO VARGAS, Recife, Brazil, 21UFG, GOIANIA, Goias, Brazil, 22UFPB, Joao Pessoa, Brazil, 23UFJF, JUIZ DE FORA, Brazil, 24UFES, Vitoria, Brazil, 25HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, 26CLINICA CIP, Goiania, Brazil, 27Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

    Background/Purpose: The COVID-19 pandemic has brought uncertainties to the rheumatological practice, and despite the large number of publications to date, many questions remain unanswered. One…
  • Abstract Number: 1531 • ACR Convergence 2021

    New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19

    Sarah Chang1, Allan Feng1, Wenzhao Meng2, Sokratis Apostolidis2, Elisabeth Mack3, Maja Artandi1, Linda Barman1, Kate Bennett4, Saborni Chakraborty1, Iris Chang1, Peggie Cheung1, Sharon Chinthrajah1, Shaurya Dhingra1, Evan Do1, Amanda Finck4, Andrew Gaano4, Reinhard Gessner5, Heather Giannini4, Joyce Gonzalez4, Sarah Greib3, Margrit Gündisch3, Alex Hsu1, Alex Kuo1, Monali Manohar1, Rong Mao1, Indira Neeli6, Andreas Neubauer3, Oluwatosin Oniyide2, Abigail Powell1, Rajan Puri1, Harald Renz3, Jeffrey Schapiro7, Payton Weidenbacher1, Rich Wittman1, Neera Ahuja1, Ho-Ryun Chung3, Pras Jagannathan1, Judith James8, Peter Kim1, Nuala Meyer2, Kari Nadeau1, Marko Radic6, William Robinson9, Upinder Singh1, Taia Wang1, John Wherry4, Chrysanthi Skevaki3, Eline Luning Prak4 and Paul Utz10, 1Stanford, San Francisco, 2University of Pennsylvania, Philadelphia, PA, 3Marburg University, Marburg, Germany, 4UPenn, Philadelphia, PA, 5University of Marburg, Marburg, Germany, 6UTHSC, Memphis, TN, 7KPNC Regional Laboratory, Berkeley, 8Oklahoma Medical Research Foundation, Oklahoma City, OK, 9Stanford University, Palo Alto, CA, 10Stanford University, Stanford, CA

    Background/Purpose: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is associated with a wide range of clinical manifestations, including autoimmune features…
  • Abstract Number: 1536 • ACR Convergence 2021

    Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease

    Sara Tedeschi1, Jack Ellrodt1, Jacklyn Stratton1, Leah Santacroce1, Paulette Chandler1, Ellen Gravallese2 and Daniel Solomon3, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, 3Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Vaccination against preventable infections is widely recommended for patients with systemic rheumatic disease. The COVID-19 pandemic has highlighted variability in attitudes toward vaccination, particularly…
  • Abstract Number: 1535 • ACR Convergence 2021

    Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination

    Rebecca Blank1, Rebecca Haberman2, Rochelle Castillo2, marie Samanovic3, Parvathy Vasudevanpillai Girija4, Paula Rackoff1, Gary Solomon5, Natalie Azar6, Pamela Rosenthal7, Peter Izmirly4, Jonathan Samuels8, Brian Golden9, Soumya Reddy7, Steven B. Abramson4, Mark Mulligan3 and Jose Scher4, 1New York University, New York, NY, 2NYU Langone Health, New York, NY, 3NYU Grossman School of Medicine, New York, NY, 4New York University School of Medicine, New York, NY, 5NYU Langone School of Medicine, Hartsdale, NY, 6NYU Langone, New York, NY, 7NYU School of Medicine, New York, NY, 8NYU Langone, Rye Brook, NY, 9NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY

    Background/Purpose: Recent studies have shown high rates of autoantibody production in patients hospitalized with COVID-19, including antinuclear antibodies (ANA) and antibodies associated with antiphospholipid syndrome.…
  • Abstract Number: 1537 • ACR Convergence 2021

    Impact of COVID-19 Infection on Patient-Reported Outcomes in Rheumatic Disease Patients: A Cross Sectional Study

    Elaine Husni1, Cassandra Calabrese2, Brittany Lapin1, Elizabeth Kirchner3 and Leonard Calabrese1, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland Heights, OH, 3CCF, Cleveland, OH

    Background/Purpose: The persistence of symptoms following COVID 19 is an area of great interest yet remains poorly understood. Long COVID symptoms are dominated by fatigue…
  • Abstract Number: 1534 • ACR Convergence 2021

    Severity Factors of Covid-19 Infection in Rheumatic Immune-mediated Inflammatory Diseases: Study in a Single University Hospital

    David Martinez-Lopez1, Diana Prieto-Peña1, Lara Sánchez-Bilbao1, Carmen Álvarez-Reguera1, Alba Herrero-Morant1, Fabricio Benavides-Villanueva1, Cristina Corrales-Selaya1, Martin Trigueros-Vazquez1, Miguel Ángel gonzalez-Gay2, Ricardo Blanco3 and Reinhard Wallmann4, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 3Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Cantabria Health Service, Santander, Spain

    Background/Purpose: Severity factors for COVID-19 have been widely studied in the general population. However, the severity factors and characteristics of COVID-19 in patients with rheumatic…
  • Abstract Number: 1540 • ACR Convergence 2021

    Antibody Response After SARS-CoV-2 Infection in Patients with Rheumatic Diseases: A Multicenter, Nationwide Study

    Ana Rita Cruz-Machado1, Sofia Carvalho Barreira1, Marc Veldhoen2, Matilde Bandeira1, Catarina Duarte3, Maria Rato4, Bruno Fernandes5, Salomé Garcia4, Filipe Pinheiro4, Miguel Bernardes4, Nathalie Madeira6, Cláudia Miguel6, Rita Torres7, Ana Bento Silva7, Carolina Mazeda8, Filipe Cunha Santos9, Marlene Sousa10, Hugo Parente11, Maria José Santos12, João Eurico Fonseca13 and Vasco C Romão13, 1Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 2Instituto de Medicina Molecular, João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 3Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 4Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, 5Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, 6Rheumatology Department, Instituto Português de Reumatologia, Lisbon, Portugal, 7Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, 8Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, 9Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, 10Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 11Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal., Ponte de Lima, Portugal, 12Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, 13Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

    Background/Purpose: The development and duration of humoral immunity after SARS-CoV-2 natural infection remains of interest. For the general population, available data suggest a robust immune…
  • Abstract Number: 1539 • ACR Convergence 2021

    High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients

    Matas Orentas1, Sonali Khandelwal2, Michael Grant2, Yanyu Zhang1, Najia Shakoor2 and Sobia Hassan1, 1RUMC, Chicago, IL, 2Rush University, Chicago, IL

    Background/Purpose: There is a need to understand which patients with rheumatologic diseases may be at highest risk for poor COVID-19 related outcomes so that both…
  • Abstract Number: 1545 • ACR Convergence 2021

    Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor

    Wonho Choi1, Soo Min Ahn2, Yong Gil Kim1, Chang-Keun Lee1, Bin Yoo2 and Seokchan Hong1, 1Asan Medical Center, Seoul, Republic of Korea, 2ASAN MEDICAL CENTER, Seoul, South Korea

    Background/Purpose: Janus kinase inhibitor (JAKi) increases the risk of the reactivation of herpes zoster (HZ) virus and may thus be temporarily discontinued in cases of…
  • Abstract Number: 1542 • ACR Convergence 2021

    Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?

    Andrew Laster1, Gordon Lam1, Sarah McCarter1, Heather Gladue2, Ahmad Kashif1, Erin Siceloff1, Victoria Lackey2, Cheryl Robertson2, Ashley Toci1 and Leonard Calabrese3, 1Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, 2Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 3Cleveland Clinic, Cleveland, OH

    Background/Purpose: Clinical trials leading to approval of the COVID19 vaccines did not include immunocompromised individuals. Concerns have been raised that immunogenicity of the vaccines may…
  • « Previous Page
  • 1
  • …
  • 601
  • 602
  • 603
  • 604
  • 605
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology